Indeed, patients with HER2-positive breast cancer respond to trastuzumab, lapatinib, and pertuzumab [16], and ALK-rearranged advanced lung tumors respond to the ALK inhibitor crizotinib [17]. This evidence concerns the gene ALK and breast carcinoma.